1
|
Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO Open 2024; 9:102981. [PMID: 38613908 PMCID: PMC11033064 DOI: 10.1016/j.esmoop.2024.102981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 03/04/2024] [Accepted: 03/04/2024] [Indexed: 04/15/2024] Open
Abstract
BACKGROUND Comprehensive genome profiling (CGP) serves as a guide for suitable genomically matched therapies for patients with cancer. However, little is known about the impact of the timing and types of cancer on the therapeutic benefit of CGP. MATERIALS AND METHODS A single hospital-based pan-cancer prospective study (TOP-GEAR; UMIN000011141) was conducted to examine the benefit of CGP with respect to the timing and types of cancer. Patients with advanced solid tumors (>30 types) who either progressed with or without standard treatments were genotyped using a single CGP test. The subjects were followed up for a median duration of 590 days to examine therapeutic response, using progression-free survival (PFS), PFS ratio, and factors associated with therapeutic response. RESULTS Among the 507 patients, 62 (12.2%) received matched therapies with an overall response rate (ORR) of 32.3%. The PFS ratios (≥1.3) were observed in 46.3% (19/41) of the evaluated patients. The proportion of subjects receiving such therapies in the rare cancer cohort was lower than that in the non-rare cancer cohort (9.6% and 17.4%, respectively; P = 0.010). However, ORR of the rare cancer patients was higher than that in the non-rare cancer cohort (43.8% and 20.0%, respectively; P = 0.046). Moreover, ORR of matched therapies in the first or second line after receiving the CGP test was higher than that in the third or later lines (62.5% and 21.7%, respectively; P = 0.003). Rare cancer and early-line treatment were significantly and independently associated with ORR of matched therapies in multivariable analysis (P = 0.017 and 0.004, respectively). CONCLUSION Patients with rare cancer preferentially benefited from tumor mutation profiling by increasing the chances of therapeutic response to matched therapies. Early-line treatments after profiling increase the therapeutic benefit, irrespective of tumor types.
Collapse
Affiliation(s)
- T Kubo
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo
| | - K Sunami
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo; Division of Genome Biology, National Cancer Center Research Institute, Tokyo
| | - T Koyama
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo
| | - M Kitami
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo
| | - Y Fujiwara
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi
| | - S Kondo
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo
| | - K Yonemori
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - E Noguchi
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - C Morizane
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo
| | - Y Goto
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - A Maejima
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo; Department of Urology, National Cancer Center Hospital, Tokyo
| | - S Iwasa
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo
| | - T Hamaguchi
- Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama
| | - A Kawai
- Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo
| | - A Arakawa
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo
| | - M Sugiyama
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo
| | - M Ohno
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo
| | - T Yoshida
- Department of Genetic Services and Medicine, National Cancer Center Hospital, Tokyo
| | - N Hiraoka
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - A Yoshida
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - M Yoshida
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - T Nishino
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo
| | - E Furukawa
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - D Narushima
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - M Nagai
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - M Kato
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - H Ichikawa
- Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo; Division of Translational Genomics, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Y Fujiwara
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - T Kohno
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo; Division of Translational Genomics, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - N Yamamoto
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo.
| |
Collapse
|
2
|
Weaver AJ, McIntosh CS, Kelly SG, Barrera GD, Lizarraga S, Hildreth KE, Williams CE, Grantham L, Yoshida T, Omert L, Bynum JA, Meledeo MA, Reddoch-Cardenas KM. Evaluating the effects of hypoxic storage on platelet function and health using a novel storage system. Transfusion 2024; 64:693-704. [PMID: 38511850 DOI: 10.1111/trf.17784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 01/14/2024] [Accepted: 03/04/2024] [Indexed: 03/22/2024]
Abstract
BACKGROUND Thousands of units of whole blood (WB) and blood components are transfused daily to treat trauma patients. Improved methods for blood storage are critical to support trauma-related care. The Hemanext ONE® system offers a unique method for hypoxic storage of WB, with successfully demonstrated storage of clinically viable RBCs. This work evaluated the system for the storage of WB, focusing on platelet health and function. STUDY DESIGN AND METHODS WB was collected from healthy donors and processed through the Hemanext ONE® system. Hemoglobin oxygen saturation (HbSO2) levels of WB were depleted to 10%, 20%, or 30% of total HbSO2 and then stored in PVC bags sealed in oxygen-impermeable bags (except for normoxic control) with samples collected on days 1, 7, and 14 post-processing. Flow cytometry assessed the activation and apoptosis of platelets. Clot dynamics were assessed based on aggregometry and thromboelastography assays, as well as thrombin generation using a calibrated-automated thrombogram method. RESULTS Hypoxic storage conditions were maintained throughout the storage period. Hypoxia triggered increased lactate production, but pH changes were negligible compared to normoxic control. Storage at 10% HbSO2 had a significant impact on platelet function, resulting in increased activation and reduced clot formation and aggregation. These effects were less significant at 20% and 30% HbSO2. DISCUSSION This study indicates that platelets are sensitive to hypoxic storage and suffer significant metabolic and functional deterioration when stored at or below 10% HbSO2.
Collapse
Affiliation(s)
- A J Weaver
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - C S McIntosh
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - S G Kelly
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - G D Barrera
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - S Lizarraga
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - K E Hildreth
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - C E Williams
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - L Grantham
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - T Yoshida
- Hemanext Inc., Lexington, Massachusetts, USA
| | - L Omert
- Hemanext Inc., Lexington, Massachusetts, USA
| | | | - M A Meledeo
- United States Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | | |
Collapse
|
3
|
Sakai K, Fuke H, Yoshimura K, Sasaki M, Abe K, Haino S, Hams T, Hasegawa M, Kim KC, Lee MH, Makida Y, Mitchell JW, Nishimura J, Nozaki M, Orito R, Ormes JF, Seo ES, Streitmatter RE, Thakur N, Yamamoto A, Yoshida T. Search for Antideuterons of Cosmic Origin Using the BESS-Polar II Magnetic-Rigidity Spectrometer. Phys Rev Lett 2024; 132:131001. [PMID: 38613296 DOI: 10.1103/physrevlett.132.131001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 10/21/2023] [Accepted: 01/10/2024] [Indexed: 04/14/2024]
Abstract
We searched for antideuterons (d[over ¯]'s) in the 4.7×10^{9} cosmic-ray events observed during the BESS-Polar II flight at solar minimum in 2007-2008 but found no candidates. The resulting 95% C.L. upper limit on the d[over ¯] flux is 6.7×10^{-5} (m^{2} s sr GeV/n)^{-1} in an energy range from 0.163 to 1.100 GeV/n. The result has improved by more than a factor of 14 from the upper limit of BESS97, which had a potential comparable to that of BESS-Polar II in the search for cosmic-origin d[over ¯]'s and was conducted during the former solar minimum. The upper limit of d[over ¯] flux from BESS-Polar II is the first result achieving the sensitivity to constrain the latest theoretical predictions.
Collapse
Affiliation(s)
- K Sakai
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - H Fuke
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
| | - K Yoshimura
- Okayama University, Okayama, Okayama 700-8530, Japan
| | - M Sasaki
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - K Abe
- Kobe University, Kobe, Hyogo 657-8501, Japan
| | - S Haino
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Hams
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - M Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K C Kim
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - M H Lee
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - Y Makida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - J W Mitchell
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - J Nishimura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - M Nozaki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - R Orito
- Kobe University, Kobe, Hyogo 657-8501, Japan
| | - J F Ormes
- University of Denver, Denver, Colorado 80208, USA
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - R E Streitmatter
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - N Thakur
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - A Yamamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Yoshida
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
| |
Collapse
|
4
|
Tamura K, Yoshida T, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO Open 2023; 8:101594. [PMID: 37517364 PMCID: PMC10485398 DOI: 10.1016/j.esmoop.2023.101594] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 06/07/2023] [Indexed: 08/01/2023] Open
Abstract
BACKGROUND Leptomeningeal metastases (LM) are devastating complications of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Although osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), has better penetration into the central nervous system than first-generation EGFR-TKIs, data on the distinct activity of EGFR-TKIs in untreated advanced EGFR-mutated NSCLC with LM are lacking. PATIENTS AND METHODS We retrospectively reviewed patients treated with EGFR-TKIs for TKI-untreated common EGFR-mutated NSCLC with LM between July 2002 and July 2021 at the National Cancer Center Hospital. The patients were divided into two groups: patients treated with osimertinib (Osi group) and those treated with gefitinib or erlotinib [first-generation (1G)-TKI group]. RESULTS Of the 967 patients, 71 were eligible, including 29 in the Osi group and 42 in the 1G-TKI group. The median progression-free survival (PFS) and overall survival (OS) in the Osi group were better than those in the 1G-TKI group (PFS: 16.9 months versus 8.6 months, P = 0.007, and OS: 26.6 months versus 20.0 months, P = 0.158). The LM-overall response rate (ORR) and LM-PFS were significantly better in the Osi group than in the 1G-TKI group (LM-ORR: 62.5% versus 25.7%, P = 0.007; LM-PFS: 23.4 months versus 12.1 months, P = 0.021). In the subgroup analysis of EGFR mutation status, LM-PFS for patients with exon 19 deletion was significantly longer in the Osi group than in the 1G-TKI group (32.7 months versus 13.4 months, P = 0.013), whereas those with L858R mutation in exon 21 did not differ between the two groups. In the multivariate analysis, osimertinib and exon 19 deletion were significant factors for better LM-PFS and OS. CONCLUSION Osimertinib can be more effective for untreated common EGFR-mutated NSCLC patients with LM, especially those with exon 19 deletion, compared to first-generation TKIs.
Collapse
Affiliation(s)
- K Tamura
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo
| | - T Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo; Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
| | - K Masuda
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - Y Matsumoto
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - Y Shinno
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - Y Okuma
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - Y Goto
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - H Horinouchi
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| | - N Yamamoto
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo; Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
| |
Collapse
|
5
|
Hayashi K, Tanaka Y, Tsuda T, Nomura A, Fujino N, Furusho H, Sakai N, Iwata Y, Usui S, Sakata K, Kato T, Tada H, Kusayama T, Usuda K, Kawashiri MA, Passman RS, Wada T, Yamagishi M, Takamura M, Fujino N, Nohara A, Kawashiri MA, Hayashi K, Sakata K, Yoshimuta T, Konno T, Funada A, Tada H, Nakanishi C, Hodatsu A, Mori M, Tsuda T, Teramoto R, Nagata Y, Nomura A, Shimojima M, Yoshida S, Yoshida T, Hachiya S, Tamura Y, Kashihara Y, Kobayashi T, Shibayama J, Inaba S, Matsubara T, Yasuda T, Miwa K, Inoue M, Fujita T, Yakuta Y, Aburao T, Matsui T, Higashi K, Koga T, Hikishima K, Namura M, Horita Y, Ikeda M, Terai H, Gamou T, Tama N, Kimura R, Tsujimoto D, Nakahashi T, Ueda K, Ino H, Higashikata T, Kaneda T, Takata M, Yamamoto R, Yoshikawa T, Ohira M, Suematsu T, Tagawa S, Inoue T, Okada H, Kita Y, Fujita C, Ukawa N, Inoguchi Y, Ito Y, Araki T, Oe K, Minamoto M, Yokawa J, Tanaka Y, Mori K, Taguchi T, Kaku B, Katsuda S, Hirase H, Haraki T, Fujioka K, Terada K, Ichise T, Maekawa N, Higashi M, Okeie K, Kiyama M, Ota M, Todo Y, Aoyama T, Yamaguchi M, Noji Y, Mabuchi T, Yagi M, Niwa S, Takashima Y, Murai K, Nishikawa T, Mizuno S, Ohsato K, Misawa K, Kokado H, Michishita I, Iwaki T, Nozue T, Katoh H, Nakashima K, Ito S, Yamagishi M. Correction: Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry. Heart Vessels 2023; 38:412. [PMID: 36508013 DOI: 10.1007/s00380-022-02218-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Kenshi Hayashi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
| | - Yoshihiro Tanaka
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Toyonobu Tsuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Akihiro Nomura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Noboru Fujino
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hiroshi Furusho
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Department of Cardiology, Ishikawa Prefectural Central Hospital, 2-1, Kuratsuki-higashi, Kanazawa, Japan
| | - Norihiko Sakai
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Yasunori Iwata
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Soichiro Usui
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Kenji Sakata
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takeshi Kato
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hayato Tada
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takashi Kusayama
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Keisuke Usuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Masa-Aki Kawashiri
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Rod S Passman
- Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Takashi Wada
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Masakazu Yamagishi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Osaka University of Human Sciences, Settsu, Osaka, Japan
| | - Masayuki Takamura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Yaginuma Y, Matsuura K, Yamada S, Yoshida T, Hasegawa M. Left ventricular outflow tract obstruction caused by a congenital accessory mitral valve leaflet and treated by open-heart surgery in a young dog. J Small Anim Pract 2023; 64:168-172. [PMID: 36284366 DOI: 10.1111/jsap.13571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2021] [Revised: 09/14/2022] [Accepted: 09/23/2022] [Indexed: 11/30/2022]
Abstract
A 3-month-old Shetland sheepdog presented with a loud ejection murmur and exercise intolerance. Echocardiography revealed an accessory mitral valve leaflet, characterised by a valve-like structure separate from the mitral valve seen in the subaortic region of the ventricular septum. The left ventricular outflow tract was partially obstructed with a pressure gradient of 12 mmHg. Accessory mitral valve leaflet resection and mitral valvuloplasty were performed during open-heart surgery. Histology performed on the membrane-like structures were indicative of fibrous connective tissues. Postoperative echocardiography confirmed removal of the valve-like structure with resolution of the left ventricular outflow tract obstruction. The pressure gradient was decreased to 4.6 mmHg. The dog was in good condition and no further treatment was required 5 months after surgery. Both cardiac troponin I and NT-proBNP were markedly decreased. In this dog, surgical resection combined with mitral valve plasty resolved the left ventricular outflow tract obstruction and the clinical signs.
Collapse
Affiliation(s)
- Y Yaginuma
- VCA Japan Shiraishi Animal Hospital, Saitama, Japan
| | - K Matsuura
- VCA Japan Shiraishi Animal Hospital, Saitama, Japan
| | - S Yamada
- VCA Japan Shiraishi Animal Hospital, Saitama, Japan
| | - T Yoshida
- VCA Japan Shiraishi Animal Hospital, Saitama, Japan
| | - M Hasegawa
- VCA Japan Shiraishi Animal Hospital, Saitama, Japan
| |
Collapse
|
7
|
Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Corrigendum to "Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation": [Annals of Oncology 28 (2017):2503-2510]. Ann Oncol 2023; 34:322. [PMID: 36075840 DOI: 10.1016/j.annonc.2022.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- H Takamatsu
- Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
| | - N Takezako
- Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan
| | - J Zheng
- Adaptive Biotechnologies Corp., South San Francisco, USA
| | - M Moorhead
- Adaptive Biotechnologies Corp., South San Francisco, USA
| | - V E H Carlton
- Adaptive Biotechnologies Corp., South San Francisco, USA
| | - K A Kong
- Adaptive Biotechnologies Corp., South San Francisco, USA
| | - R Murata
- Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan
| | - S Ito
- Department of Medical Oncology, Iwate Medical University School of Medicine, Morioka, Japan
| | - T Miyamoto
- Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Yokoyama
- Department of Hematology/Oncology, Tokai University Hachioji Hospital, Hachioji, Japan
| | - K Matsue
- Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
| | - T Sato
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - T Kurokawa
- Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan
| | - H Yagi
- Department of Hematology, Kinki University School of Medicine Nara Hospital, Ikoma, Nara, Japan
| | - Y Terasaki
- Division of Internal Medicine, Toyama City Hospital, Toyama, Japan
| | - K Ohata
- Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - M Matsumoto
- Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan
| | - T Yoshida
- Department of Hematology, Shizuoka City Shimizu Hospital, Shizuoka, Japan
| | - M Faham
- Adaptive Biotechnologies Corp., South San Francisco, USA
| | - S Nakao
- Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| |
Collapse
|
8
|
Ikeda J, Ohe C, Tanaka N, Yoshida T, Saito R, Atsumi N, Kobayashi T, Hidefumi K, Koji T, Takeharu S. HIF-1 activator Mint3 promotes tumor progression in urothelial carcinoma. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01220-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Sukhanov S, Higashi Y, Yoshida T, Danchuk S, Alfortish M, Goodchild T, Scarboroogh A, Sharp T, Schumacher J, Sindi F, Bowles D, Ivy J, Tharp D, Rozenbaum Z, Jenkins J, Garcia D, Lefer D, Kolls J, Delafontaine P. Insulin-like growth factor I reduces human-like coronary atherosclerosis. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00012-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
10
|
Sindi F, Delafontaine P, Yoshida T. Angiotensin II-mediated suppression of skeletal muscle autophagy via mtor And Foxo3a pathways. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00111-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
11
|
Yoshida T, Lott CS, Sukhanov S, Delafontaine P. Regulation of collagen synthesis and fibrosis development in skeletal muscle by LARP6. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00631-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
12
|
Yoshida T, Takahiro N, Chisato O, Junichi I, Yoshiki Y, Naho A, Ryoichi S, Koji T, Hidefumi K. LAG-3/FGL1 axis predicts response to immune checkpoint inhibitors in advanced urothelial carcinoma. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00582-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
13
|
Taheri S, Yoshida T, Böker KO, Foerster RH, Jochim L, Flux AL, Grosskopf B, Hawellek T, Lehmann W, Schilling AF. Changes of the subchondral bone microchannel network in early osteoarthritis. Osteoarthritis Cartilage 2023; 31:49-59. [PMID: 36243309 DOI: 10.1016/j.joca.2022.10.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 08/08/2022] [Accepted: 10/04/2022] [Indexed: 11/21/2022]
Abstract
OBJECTIVE We have identified a 3D network of subchondral microchannels that connects the deep zone of cartilage to the bone marrow (i.e., cartilage-bone marrow microchannel connectors; CMMC). However, the pathological significance of CMMC is largely unknown. Here, we quantitatively evaluated how the CMMC microarchitecture is related to cartilage condition, as well as regional differences in early idiopathic osteoarthritis (OA). METHODS Two groups of cadaveric female human femoral heads (intact cartilage vs early cartilage lesions) were identified, and a biopsy-based high-resolution micro-CT imaging was employed. Subchondral bone (SB) thickness, CMMC number, maximum and minimum CMMC size, and the CMMC morphology were quantified and compared between the two groups. The effect of joint's region and cartilage condition was examined on each dependent variable. RESULTS The CMMC number and morphology were affected by region of the joint, but not by cartilage condition. On the other hand, the minimum and maximum CMMC size was changed by both the location on the joint, as well as the cartilage condition. The smallest CMMC were consistently detected at the load-bearing region (LBR) of the joint. Compared to non-pathological subjects, the size of the microchannels was enlarged in early OA, most noticeably at the non-load-bearing region (NLBR) and the peripheral rim (PR) of the femoral head. Furthermore, subchondral bone thinning was observed in early OA as a localized occurrence linked with areas of partial chondral defect. CONCLUSION Our data point to an enlargement of the SB microchannel network, and a collective structural deterioration of SB in early idiopathic OA.
Collapse
Affiliation(s)
- S Taheri
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany.
| | - T Yoshida
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - K O Böker
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - R H Foerster
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - L Jochim
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - A L Flux
- University of Göttingen Johann-Friedrich-Blumenbach-Institute for Zoology & Anthropology, Department of Historical Anthropology and Human Ecology, Göttingen, Germany
| | - B Grosskopf
- University of Göttingen Johann-Friedrich-Blumenbach-Institute for Zoology & Anthropology, Department of Historical Anthropology and Human Ecology, Göttingen, Germany
| | - T Hawellek
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - W Lehmann
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - A F Schilling
- Department of Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| |
Collapse
|
14
|
Watanabe D, Yoshida T, Nanri H, Watanabe Y, Itoi A, Goto C, Ishikawa-Takata K, Yamada Y, Fujita H, Miyachi M, Kimura M. Dose-Response Relationships between Diet Quality and Mortality among Frail and Non-Frail Older Adults: A Population-Based Kyoto-Kameoka Prospective Cohort Study. J Nutr Health Aging 2023; 27:1228-1237. [PMID: 38151874 DOI: 10.1007/s12603-023-2041-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 11/12/2023] [Indexed: 12/29/2023]
Abstract
OBJECTIVES Although better diet quality is inversely associated with mortality risk, the association between diet quality and mortality remains unclear in frail and non-frail older adults. Thus, we aimed to examine this association in older Japanese adults. DESIGN A prospective cohort study. SETTING AND PARTICIPANTS We used the data of 8,051 Japanese older adults aged ≥65 years in the Kyoto-Kameoka study. MESUREMENTS Dietary intake was estimated using a validated food frequency questionnaire. Diet quality was evaluated by calculating the adherence scores to the Japanese Food Guide Spinning Top (range, 0 [worst] to 80 [best]), which were stratified into quartiles. Frailty status was assessed using the validated self-administered Kihon Checklist (KCL) and the Fried phenotype (FP) model. Survival data were collected between February 15, 2012 and November 30, 2016. Statistical analysis was performed using the multivariate Cox proportional hazard analysis and the spline model. RESULTS During the median 4.75-year follow-up (36,552 person-years), we recorded 661 deaths. After adjusting for confounders, compared with the bottom adherence score quartile, the top quartile was associated with lower hazard ratio (HR) of mortality in frailty (HR, 0.73; 95% confidence interval [CI], 0.54-1.00) and non-frailty, as defined by the KCL (HR, 0.72; 95% CI, 0.52-1.01). In the spline model, regardless of frailty status defined by the KCL and FP model, adherence score showed a strongly dose-dependent inverse association with mortality up to approximately 55 points; however, no significant differences were observed thereafter. This association was similar to the results obtained in individuals with physical, cognitive, and depression as domains of KCL in the spline model. CONCLUSIONS Our findings demonstrate an L-shaped association between diet quality and mortality in both frail and non-frail individuals. This study may provide important knowledge for improving poor diet quality in older individuals with frailty or domains of frailty.
Collapse
Affiliation(s)
- D Watanabe
- Daiki Watanabe, RD, PhD, Faculty of Sport Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa-city, Saitama 359-1192, Japan. Tel.: +81-4-2947-6936. E-mail:
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Murata S, Horinouchi H, Morishita M, Kaku S, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Okuma K, Kusumoto M, Ohe Y. 309P Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
16
|
Nakayama T, Oishi M, Weng J, Omori K, Kwon C, Nakazawa T, Nishibata T, Kinugasa F, Yoshida T, Nagasaka Y. 42P Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
17
|
Yoshida T, Fujisaka Y, Kurata T, Yamamoto N, Thomas A, Sarholz B, Hallwachs R, Bolleddula J, Kuronita T, Moulin Correa C, Paz-Ares L. 1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Tateishi A, Okuma Y, Goto Y, Arakaki M, Shinno Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. 1635P Impact of treatment sequence on clinical outcomes in patients with thymic carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
19
|
Shirasawa M, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Watanabe SI, Ohe Y. 1548P Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
20
|
Uematsu M, Goto Y, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. EP07.03-004 Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Guérin L, Yoshida T, Simonov A, Toudic B, Takaishi S, Yamashita M. Elucidating 2D charge-density-wave atomic structure in an MX-chain by the 3D-Δ pair distribution function method. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322095699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
22
|
Beck L, Boguniewicz M, Hata T, Fuxench Z, Simpson E, De Benedetto A, Ko J, Ong P, Yoshida T, Gallo R, Lussier S, David G, Schlievert P, Gill S, Rudman Spergel A, Leung D. 519 Rapid reduction in S. aureus & cytotoxins in dupilumab treated atopic dermatitis subjects. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Kimura M, Yoshimura I, Yanagida K, Yoshida T, Hagiwara K, Kaneko T, Yamada Y, Nakagawa T. Evaluation of ejaculation function using a simple questionnaire. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.03.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland KR, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d'Ascenzo N, Datta M, de Barbaro P, Demortier L, Deninno M, D'Errico M, Devoto F, Di Canto A, Di Ruzza B, Dittmann JR, Donati S, D'Onofrio M, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Farrington S, Fernández Ramos JP, Field R, Flanagan G, Forrest R, Franklin M, Freeman JC, Frisch H, Funakoshi Y, Galloni C, Garfinkel AF, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grosso-Pilcher C, Guimaraes da Costa J, Hahn SR, Han JY, Happacher F, Hara K, Hare M, Harr RF, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes RE, Husemann U, Hussein M, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jindariani S, Jones M, Joo KK, Jun SY, Junk TR, Kambeitz M, Kamon T, Karchin PE, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen AT, Lammel S, Lancaster M, Lannon K, Latino G, Lee HS, Lee JS, Leo S, Leone S, Lewis JD, Limosani A, Lipeles E, Lister A, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Marchese L, Margaroli F, Marino P, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Menzione A, Mesropian C, Miao T, Michielin E, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello MJ, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Nigmanov T, Nodulman L, Noh SY, Norniella O, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Pranko A, Prokoshin F, Ptohos F, Punzi G, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner JL, Ruffini F, Ruiz A, Russ J, Rusu V, Sakumoto WK, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt EE, Schwarz T, Scodellaro L, Scuri F, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sliwa K, Smith JR, Snider FD, Song H, Sorin V, St Denis R, Stancari M, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis K, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang SM, Waters D, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Wilson JS, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfmeister H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Zanetti AM, Zeng Y, Zhou C, Zucchelli S. High-precision measurement of the W boson mass with the CDF II detector. Science 2022; 376:170-176. [PMID: 35389814 DOI: 10.1126/science.abk1781] [Citation(s) in RCA: 77] [Impact Index Per Article: 38.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The mass of the W boson, a mediator of the weak force between elementary particles, is tightly constrained by the symmetries of the standard model of particle physics. The Higgs boson was the last missing component of the model. After observation of the Higgs boson, a measurement of the W boson mass provides a stringent test of the model. We measure the W boson mass, MW, using data corresponding to 8.8 inverse femtobarns of integrated luminosity collected in proton-antiproton collisions at a 1.96 tera-electron volt center-of-mass energy with the CDF II detector at the Fermilab Tevatron collider. A sample of approximately 4 million W boson candidates is used to obtain [Formula: see text], the precision of which exceeds that of all previous measurements combined (stat, statistical uncertainty; syst, systematic uncertainty; MeV, mega-electron volts; c, speed of light in a vacuum). This measurement is in significant tension with the standard model expectation.
Collapse
Affiliation(s)
| | - T Aaltonen
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - S Amerio
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Amidei
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Anastassov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Annovi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Antos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - G Apollinari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J A Appel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - A Artikov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - J Asaadi
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Ashmanskas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B Auerbach
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - A Aurisano
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - F Azfar
- University of Oxford, Oxford OX1 3RH, UK
| | - W Badgett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Bae
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A Barbaro-Galtieri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - V E Barnes
- Purdue University, West Lafayette, IN 47907, USA
| | - B A Barnett
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - P Barria
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - P Bartos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - M Bauce
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Bedeschi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Behari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Bellettini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - J Bellinger
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | | | - A Beretvas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Bhatti
- The Rockefeller University, New York, NY 10065, USA
| | - K R Bland
- Baylor University, Waco, TX 76798, USA
| | - B Blumenfeld
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - A Bocci
- Duke University, Durham, NC 27708, USA
| | - A Bodek
- University of Rochester, Rochester, NY 14627, USA
| | - D Bortoletto
- Purdue University, West Lafayette, IN 47907, USA
| | - J Boudreau
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - A Boveia
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - L Brigliadori
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - C Bromberg
- Michigan State University, East Lansing, MI 48824, USA
| | - E Brucken
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - J Budagov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - H S Budd
- University of Rochester, Rochester, NY 14627, USA
| | - K Burkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Busetto
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - P Bussey
- Glasgow University, Glasgow G12 8QQ, UK
| | - P Butti
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - A Buzatu
- Glasgow University, Glasgow G12 8QQ, UK
| | - A Calamba
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - S Camarda
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - B Carls
- University of Illinois, Urbana, IL 61801, USA
| | - D Carlsmith
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - R Carosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Carrillo
- University of Florida, Gainesville, FL 32611, USA
| | - B Casal
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Casarsa
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - A Castro
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - P Catastini
- Harvard University, Cambridge, MA 02138, USA
| | - D Cauz
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - V Cavaliere
- University of Illinois, Urbana, IL 61801, USA
| | - A Cerri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - L Cerrito
- University College London, London WC1E 6BT, UK
| | - Y C Chen
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - M Chertok
- University of California, Davis, Davis, CA 95616, USA
| | - G Chiarelli
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - G Chlachidze
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Cho
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - D Chokheli
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - A Clark
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - C Clarke
- Wayne State University, Detroit, MI 48201, USA
| | - M E Convery
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Conway
- University of California, Davis, Davis, CA 95616, USA
| | - M Corbo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Cordelli
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - C A Cox
- University of California, Davis, Davis, CA 95616, USA
| | - D J Cox
- University of California, Davis, Davis, CA 95616, USA
| | - M Cremonesi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - D Cruz
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - J Cuevas
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - R Culbertson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N d'Ascenzo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Datta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P de Barbaro
- University of Rochester, Rochester, NY 14627, USA
| | - L Demortier
- The Rockefeller University, New York, NY 10065, USA
| | - M Deninno
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - M D'Errico
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Devoto
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Di Canto
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - B Di Ruzza
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - S Donati
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - M D'Onofrio
- University of Liverpool, Liverpool L69 7ZE, UK
| | - M Dorigo
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,University of Trieste, I-34127 Trieste, Italy
| | - A Driutti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Ebina
- Waseda University, Tokyo 169, Japan
| | - R Edgar
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Elagin
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - R Erbacher
- University of California, Davis, Davis, CA 95616, USA
| | - S Errede
- University of Illinois, Urbana, IL 61801, USA
| | - B Esham
- University of Illinois, Urbana, IL 61801, USA
| | | | - J P Fernández Ramos
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - R Field
- University of Florida, Gainesville, FL 32611, USA
| | - G Flanagan
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - R Forrest
- University of California, Davis, Davis, CA 95616, USA
| | - M Franklin
- Harvard University, Cambridge, MA 02138, USA
| | - J C Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Frisch
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - C Galloni
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | | | - P Garosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H Gerberich
- University of Illinois, Urbana, IL 61801, USA
| | - E Gerchtein
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Giagu
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - V Giakoumopoulou
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - K Gibson
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C M Ginsburg
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Giokaris
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - P Giromini
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - V Glagolev
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - D Glenzinski
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Gold
- University of New Mexico, Albuquerque, NM 87131, USA
| | - D Goldin
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - A Golossanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Gomez
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | | | - M Goncharov
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - O González López
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - I Gorelov
- University of New Mexico, Albuquerque, NM 87131, USA
| | | | - K Goulianos
- The Rockefeller University, New York, NY 10065, USA
| | - E Gramellini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C Grosso-Pilcher
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Y Han
- University of Rochester, Rochester, NY 14627, USA
| | - F Happacher
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - K Hara
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Hare
- Tufts University, Medford, MA 02155, USA
| | - R F Harr
- Wayne State University, Detroit, MI 48201, USA
| | | | | | - C Hays
- University of Oxford, Oxford OX1 3RH, UK
| | - J Heinrich
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Herndon
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - A Hocker
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Z Hong
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Hopkins
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Hou
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - R E Hughes
- The Ohio State University, Columbus, OH 43210, USA
| | - U Husemann
- Yale University, New Haven, CT 06520, USA
| | - M Hussein
- Michigan State University, East Lansing, MI 48824, USA
| | - J Huston
- Michigan State University, East Lansing, MI 48824, USA
| | - G Introzzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Istituto Nazionale di Fisica Nucleare Pavia, I-27100 Pavia, Italy.,University of Pavia, I-27100 Pavia, Italy
| | - M Iori
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy.,Sapienza Università di Roma, I-00185 Roma, Italy
| | - A Ivanov
- University of California, Davis, Davis, CA 95616, USA
| | - E James
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Jang
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - B Jayatilaka
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E J Jeon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Jindariani
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Jones
- Purdue University, West Lafayette, IN 47907, USA
| | - K K Joo
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Y Jun
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - T R Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Kambeitz
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - T Kamon
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA.,Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - P E Karchin
- Wayne State University, Detroit, MI 48201, USA
| | - A Kasmi
- Baylor University, Waco, TX 76798, USA
| | - Y Kato
- Osaka City University, Osaka 558-8585, Japan
| | - W Ketchum
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - J Keung
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - B Kilminster
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D H Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - H S Kim
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J E Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - M J Kim
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - S H Kim
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S B Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y J Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y K Kim
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - N Kimura
- Waseda University, Tokyo 169, Japan
| | - M Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Kondo
- Waseda University, Tokyo 169, Japan
| | - D J Kong
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J Konigsberg
- University of Florida, Gainesville, FL 32611, USA
| | | | - M Kreps
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - J Kroll
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Kruse
- Duke University, Durham, NC 27708, USA
| | - T Kuhr
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - M Kurata
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A T Laasanen
- Purdue University, West Lafayette, IN 47907, USA
| | - S Lammel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Lancaster
- University College London, London WC1E 6BT, UK
| | - K Lannon
- The Ohio State University, Columbus, OH 43210, USA
| | - G Latino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Leo
- University of Illinois, Urbana, IL 61801, USA
| | - S Leone
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - J D Lewis
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - E Lipeles
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A Lister
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Q Liu
- Purdue University, West Lafayette, IN 47907, USA
| | - T Liu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Lockwitz
- Yale University, New Haven, CT 06520, USA
| | - A Loginov
- Yale University, New Haven, CT 06520, USA
| | - D Lucchesi
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - A Lucà
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Lueck
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Lujan
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Lungu
- The Rockefeller University, New York, NY 10065, USA
| | - J Lys
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - R Lysak
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - R Madrak
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Maestro
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - S Malik
- The Rockefeller University, New York, NY 10065, USA
| | - G Manca
- University of Liverpool, Liverpool L69 7ZE, UK
| | | | - L Marchese
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - F Margaroli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - P Marino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - K Matera
- University of Illinois, Urbana, IL 61801, USA
| | - M E Mattson
- Wayne State University, Detroit, MI 48201, USA
| | - A Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Mazzanti
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - R McNulty
- University of Liverpool, Liverpool L69 7ZE, UK
| | - A Mehta
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P Mehtala
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Menzione
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - C Mesropian
- The Rockefeller University, New York, NY 10065, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Michielin
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Mietlicki
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Mitra
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - H Miyake
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Moed
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Moggi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C S Moon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - R Moore
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M J Morello
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - A Mukherjee
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Th Muller
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Murat
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Mussini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - J Nachtman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Y Nagai
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | | | - I Nakano
- Okayama University, Okayama 700-8530, Japan
| | - A Napier
- Tufts University, Medford, MA 02155, USA
| | - J Nett
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - T Nigmanov
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - L Nodulman
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Y Noh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - O Norniella
- University of Illinois, Urbana, IL 61801, USA
| | - L Oakes
- University of Oxford, Oxford OX1 3RH, UK
| | - S H Oh
- Duke University, Durham, NC 27708, USA
| | - Y D Oh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - T Okusawa
- Osaka City University, Osaka 558-8585, Japan
| | - R Orava
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - L Ortolan
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | - C Pagliarone
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - E Palencia
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - P Palni
- University of New Mexico, Albuquerque, NM 87131, USA
| | - V Papadimitriou
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W Parker
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - G Pauletta
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - M Paulini
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - C Paus
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - G Piacentino
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Pianori
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J Pilot
- University of California, Davis, Davis, CA 95616, USA
| | - K Pitts
- University of Illinois, Urbana, IL 61801, USA
| | - C Plager
- University of California, Los Angeles, Los Angeles, CA 90024, USA
| | - L Pondrom
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - S Poprocki
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Potamianos
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - A Pranko
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - F Prokoshin
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Ptohos
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - G Punzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - I Redondo Fernández
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - P Renton
- University of Oxford, Oxford OX1 3RH, UK
| | - M Rescigno
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - F Rimondi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - L Ristori
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - A Robson
- Glasgow University, Glasgow G12 8QQ, UK
| | - T Rodriguez
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - S Rolli
- Tufts University, Medford, MA 02155, USA
| | - M Ronzani
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - R Roser
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J L Rosner
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - F Ruffini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - A Ruiz
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Russ
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - V Rusu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W K Sakumoto
- University of Rochester, Rochester, NY 14627, USA
| | | | - L Santi
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Sato
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - V Saveliev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Savoy-Navarro
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E E Schmidt
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Schwarz
- University of Michigan, Ann Arbor, MI 48109, USA
| | - L Scodellaro
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - F Scuri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Seidel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Seiya
- Osaka City University, Osaka 558-8585, Japan
| | - A Semenov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Sforza
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - S Z Shalhout
- University of California, Davis, Davis, CA 95616, USA
| | - T Shears
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P F Shepard
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - M Shimojima
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Shochet
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - I Shreyber-Tecker
- Institution for Theoretical and Experimental Physics, ITEP, Moscow 117259, Russia
| | - A Simonenko
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Sliwa
- Tufts University, Medford, MA 02155, USA
| | - J R Smith
- University of California, Davis, Davis, CA 95616, USA
| | - F D Snider
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Song
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - V Sorin
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - M Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Stentz
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Strologas
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Sudo
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A Sukhanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - I Suslov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Takemasa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Takeuchi
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J Tang
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - M Tecchio
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P K Teng
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - J Thom
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Thomson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - V Thukral
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - D Toback
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - S Tokar
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - K Tollefson
- Michigan State University, East Lansing, MI 48824, USA
| | - T Tomura
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Torre
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Totaro
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy
| | - M Trovato
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - F Ukegawa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Uozumi
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - F Vázquez
- University of Florida, Gainesville, FL 32611, USA
| | - G Velev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Vellidis
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - C Vernieri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - M Vidal
- Purdue University, West Lafayette, IN 47907, USA
| | - R Vilar
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Vizán
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Vogel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - G Volpi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - P Wagner
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - R Wallny
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S M Wang
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - D Waters
- University College London, London WC1E 6BT, UK
| | - W C Wester
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Whiteson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A B Wicklund
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Wilbur
- University of California, Davis, Davis, CA 95616, USA
| | - H H Williams
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J S Wilson
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P Wilson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B L Winer
- The Ohio State University, Columbus, OH 43210, USA
| | - P Wittich
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Wolbers
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - T Wright
- University of Michigan, Ann Arbor, MI 48109, USA
| | - X Wu
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Z Wu
- Baylor University, Waco, TX 76798, USA
| | - K Yamamoto
- Osaka City University, Osaka 558-8585, Japan
| | - D Yamato
- Osaka City University, Osaka 558-8585, Japan
| | - T Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - U K Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y C Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - W-M Yao
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - G P Yeh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yi
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Yoh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yorita
- Waseda University, Tokyo 169, Japan
| | - T Yoshida
- Osaka City University, Osaka 558-8585, Japan
| | - G B Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - I Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A M Zanetti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - Y Zeng
- Duke University, Durham, NC 27708, USA
| | - C Zhou
- Duke University, Durham, NC 27708, USA
| | - S Zucchelli
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| |
Collapse
|
25
|
El-Husseiny HM, Mady EA, Shimada K, Hamabe L, Yoshida T, Ma D, Mandour AS, Hendawy H, Sasaki K, Fukuzumi S, Watanabe M, Hirose M, Mizuki H, Takahashi K, Tanaka R. Intraventricular pressure gradient: a promising tool to predict the post-infarction chronic congestive heart failure in rats. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeab289.390] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background/Introduction: Congestive heart failure (CHF), the main reason for morbidity and mortality, is considered a serious consequence of myocardial infarction (MI). The use of left ventricular end-diastolic pressure (LVEDP) as a chief indicator of CHF becomes limited because of the possible impairment of cardiac function and induced aortic valve damage during its recording. Echocardiography is the gold standard approach to diagnose structural myocardial dysfunction. However, its ability to predict chronic CHF following MI is still limited. Recently, intraventricular pressure gradient (IVPG) was presented as a non-invasive, highly sensitive preload-independent diastolic function parameter to assess cardiac function, especially during cardiomyopathy. However, there have not been any investigations demonstrating the feasibility of IVPG in the evaluation of post-infarction chronic CHF.
Purpose
This study aimed to investigate the utility of IVPG to assess the heart function in a rat model with chronic CHF following MI with evaluating its capacity to predict these changes.
Methods
Fifty male rats were included. MI was induced via ligation of the left anterior descending artery (LAD) at the level of the atrioventricular junction (MI animals, n = 35). Sham animals were subjected to the same left thoracotomy procedure without LAD ligation (Sham animals, n = 15). Transthoracic conventional echocardiography and colour M-mode echocardiography (CMME) for IVPG were performed in all animals 6 months post-surgery. The next day, animals were anesthetized, ventilated, and euthanized after the recording of hemodynamics. The heart weight, and lung and liver wet-to-dry weight ratios were recorded. J-tree cluster-analysis was performed based on ten echocardiographic variables indicative of CHF.
Results
Based on the cluster analysis, animals were joined into two clusters; CHF+ (n = 22) and named MI/HF+, and CHF- (n = 28) that was joined from sham (n = 15), and MI/HF- (n = 13). MI/HF+ presented the most severe anatomical and echocardiographic changes indicative of CHF with significant reduction of all IVPG indices and impairment of the hemodynamics. The IVPG indices were significantly (P< 0.0001) correlated with the anatomical and echocardiographic findings, LVDP, LVEDP, HR, -dP/dtmin, and Tau. Meanwhile, LVSP was only significantly correlated with apical IVPG (R = 0.677, P = 0.022). dP/dtmax was significantly correlated with total IVPG, basal IVPG, and apical IVPG (R = 0.797, P = 0.017, R = 0.724, P = 0.003, and R = 0.652, P = 0.026 ; respectively). Moreover, total, basal, mid-to-apical, mid-, and apical IVPG were significant (P< 0.0001) predictors of chronic CHF following MI.
Conclusion
Compared to the structural, and functional indices of conventional echocardiography, IVPG derived from CMME could provide a substantial non-invasive tool to diagnose and predict CHF after long-term MI.
Collapse
Affiliation(s)
- HM El-Husseiny
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - EA Mady
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - K Shimada
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - L Hamabe
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - T Yoshida
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - D Ma
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - AS Mandour
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - H Hendawy
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - K Sasaki
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - S Fukuzumi
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - M Watanabe
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - M Hirose
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - H Mizuki
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| | - K Takahashi
- Juntendo University Graduate School of Medicine, Department of Pediatrics and Adolescent Medicine, Tokyo, Japan
| | - R Tanaka
- Tokyo university of agriculture and technology, Fuchu, Tokyo, Japan
| |
Collapse
|
26
|
Sekine Y, Iwasaki Y, Aoi T, Mikiko E, Hirata M, Kamatani Y, Matsuda K, Kokichi S, Yoshida T, Murakami Y, Fukui T, Akamatsu S, Ogawa O, Nakagawa H, Numakura K, Narita S, Momozawa Y, Habuchi T. Large-scale genomic analysis of renal cell carcinoma using 1,532 Japanese patients and 5,996 controls. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01200-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Fukui S, Yoshida T, Takemoto K, Kinoshita H. Evaluating the encrustation features due to the short-term ureteral stent placement using micro-computed tomography: The results from a prospective study. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01119-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Yoshida T, Matsunaga T, Noriko T, Kinoshita H, Youichi H. Development of an automated irrigation system synchronized with an ultra miniature fiber optic pressure sensor for regulating intrapelvic pressure during ureteroscopy: An ex vivo preclinical study. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01266-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Nanri H, Watanabe D, Yoshida T, Yoshimura E, Okabe Y, Ono M, Koizumi T, Kobayashi H, Fujita H, Kimura M, Yamada Y. Adequate Protein Intake on Comprehensive Frailty in Older Adults: Kyoto-Kameoka Study. J Nutr Health Aging 2022; 26:161-168. [PMID: 35166309 DOI: 10.1007/s12603-022-1740-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Defining an adequate protein intake in older adults remains unresolved. We examined the association between calibrated protein intake and comprehensive frailty by sex in the Kyoto-Kameoka study. DESIGN Cross-sectional study of baseline data. SETTING AND PARTICIPANTS The study included 5679 Japanese participants aged 65 years or older. METHODS Calibration coefficients were estimated from food frequency questionnaires and 7-day dietary records as a reference. Comprehensive frailty was evaluated using the 25-item Kihon Checklist (KCL) and defined as a total KCL score of ≥7points. Sex-specific calibrated protein intakes were presented as % of energy, per kg of actual body weight (BW), and per kg of ideal BW. RESULTS Multiple logistic regression analysis showed that calibrated protein intake is inversely associated with comprehensive frailty. The association between protein intake and comprehensive frailty was also evaluated using curve fitting with non-linear regression, a weak U-shaped association was found in males and an L-shaped association in females. Men had a low prevalence of frailty at a calibrated protein intake of 15-17% energy from protein, 1.2 g/kg actual BW/day, or 1.4 g/kg ideal BW/day, and women had a low prevalence of frailty at 17-21% energy from protein or 1.6 g/kg ideal BW/day, with the prevalence of frailty remaining unchanged at higher protein intakes. Meanwhile, the inverse relationship between protein intake per ABW and frailty showed a gradual decrease at 1.4 g/kg ABW/day for protein in women. CONCLUSIONS AND IMPLICATIONS A non-linear relationship was found between calibrated protein intake and frailty, with a U-shaped association in men and an L-shaped association in women. Adequate protein intake in healthy Japanese older adults was higher than the current recommended daily allowance.
Collapse
Affiliation(s)
- H Nanri
- Hinako Nanri, Department of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan, E-mail:
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abe K, Bronner C, Hayato Y, Hiraide K, Ikeda M, Imaizumi S, Kameda J, Kanemura Y, Kataoka Y, Miki S, Miura M, Moriyama S, Nagao Y, Nakahata M, Nakayama S, Okada T, Okamoto K, Orii A, Pronost G, Sekiya H, Shiozawa M, Sonoda Y, Suzuki Y, Takeda A, Takemoto Y, Takenaka A, Tanaka H, Watanabe S, Yano T, Han S, Kajita T, Okumura K, Tashiro T, Xia J, Megias G, Bravo-Berguño D, Labarga L, Marti L, Zaldivar B, Pointon B, Blaszczyk F, Kearns E, Raaf J, Stone J, Wan L, Wester T, Bian J, Griskevich N, Kropp W, Locke S, Mine S, Smy M, Sobel H, Takhistov V, Hill J, Kim J, Lim I, Park R, Bodur B, Scholberg K, Walter C, Cao S, Bernard L, Coffani A, Drapier O, El Hedri S, Giampaolo A, Gonin M, Mueller T, Paganini P, Quilain B, Ishizuka T, Nakamura T, Jang J, Learned J, Anthony L, Martin D, Scott M, Sztuc A, Uchida Y, Berardi V, Catanesi M, Radicioni E, Calabria N, Machado L, De Rosa G, Collazuol G, Iacob F, Lamoureux M, Mattiazzi M, Ospina N, Ludovici L, Maekawa Y, Nishimura Y, Friend M, Hasegawa T, Ishida T, Kobayashi T, Jakkapu M, Matsubara T, Nakadaira T, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Kotsar Y, Nakano Y, Ozaki H, Shiozawa T, Suzuki A, Takeuchi Y, Yamamoto S, Ali A, Ashida Y, Feng J, Hirota S, Kikawa T, Mori M, Nakaya T, Wendell R, Yasutome K, Fernandez P, McCauley N, Mehta P, Tsui K, Fukuda Y, Itow Y, Menjo H, Niwa T, Sato K, Tsukada M, Lagoda J, Lakshmi S, Mijakowski P, Zalipska J, Jiang J, Jung C, Vilela C, Wilking M, Yanagisawa C, Hagiwara K, Harada M, Horai T, Ishino H, Ito S, Kitagawa H, Koshio Y, Ma W, Piplani N, Sakai S, Barr G, Barrow D, Cook L, Goldsack A, Samani S, Wark D, Nova F, Boschi T, Di Lodovico F, Gao J, Migenda J, Taani M, Zsoldos S, Yang J, Jenkins S, Malek M, McElwee J, Stone O, Thiesse M, Thompson L, Okazawa H, Kim S, Seo J, Yu I, Nishijima K, Koshiba M, Iwamoto K, Nakagiri K, Nakajima Y, Ogawa N, Yokoyama M, Martens K, Vagins M, Kuze M, Izumiyama S, Yoshida T, Inomoto M, Ishitsuka M, Ito H, Kinoshita T, Matsumoto R, Ohta K, Shinoki M, Suganuma T, Ichikawa A, Nakamura K, Martin J, Tanaka H, Towstego T, Akutsu R, Gousy-Leblanc V, Hartz M, Konaka A, de Perio P, Prouse N, Chen S, Xu B, Zhang Y, Posiadala-Zezula M, Hadley D, O’Flaherty M, Richards B, Jamieson B, Walker J, Minamino A, Okamoto K, Pintaudi G, Sano S, Sasaki R. Diffuse supernova neutrino background search at Super-Kamiokande. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.122002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
31
|
Ideta S, Johnston S, Yoshida T, Tanaka K, Mori M, Anzai H, Ino A, Arita M, Namatame H, Taniguchi M, Ishida S, Takashima K, Kojima KM, Devereaux TP, Uchida S, Fujimori A. Hybridization of Bogoliubov Quasiparticles between Adjacent CuO_{2} Layers in the Triple-Layer Cuprate Bi_{2}Sr_{2}Ca_{2}Cu_{3}O_{10+δ} Studied by Angle-Resolved Photoemission Spectroscopy. Phys Rev Lett 2021; 127:217004. [PMID: 34860085 DOI: 10.1103/physrevlett.127.217004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 07/08/2021] [Accepted: 10/20/2021] [Indexed: 06/13/2023]
Abstract
Hybridization of Bogoliubov quasiparticles (BQPs) between the CuO_{2} layers in the triple-layer cuprate high-temperature superconductor Bi_{2}Sr_{2}Cu_{2}Cu_{3}O_{10+δ} is studied by angle-resolved photoemission spectroscopy (ARPES). In the superconducting state, an anticrossing gap opens between the outer- and inner-BQP bands, which we attribute primarily to interlayer single-particle hopping with possible contributions from interlayer Cooper pairing. We find that the d-wave superconducting gap of both BQP bands smoothly develops with momentum without an abrupt jump in contrast to a previous ARPES study. Hybridization between the BQPs also gradually increases in going from the off nodal to the antinodal region, which is explained by the momentum dependence of the interlayer single-particle hopping. As possible mechanisms for the enhancement of the superconducting transition temperature, the hybridization between the BQPs as well as the combination of phonon modes of the triple CuO_{2} layers and spin fluctuations represented by a four-well model are discussed.
Collapse
Affiliation(s)
- S Ideta
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee 37996, USA
| | - T Yoshida
- Department of Human and Environmental studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - K Tanaka
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - M Mori
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
| | - H Anzai
- Graduate School of Engineering, Osaka Prefecture University, Sakai 599-8531, Japan
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - A Ino
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
- Department of Education and Creation Engineering, Kurume Institute of Technology, Fukuoka 2286-66, Japan
| | - M Arita
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - H Namatame
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - M Taniguchi
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - S Ishida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - K Takashima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - K M Kojima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- J-PARC Center and Institute of Materials Structure Science, KEK, Tsukuba, Ibaraki 305-0801, Japan
- Centre for Molecular and Materials Science, TRIUMF, 4004 Vancouver, Canada
| | - T P Devereaux
- Geballe Laboratory for Advanced Materials, Stanford University, Stanford, California 94305, USA
- Stanford Institute for Materials and Energy Sciences, SLAC National Laboratory and Stanford University, Menlo Park, California 94025, USA
- Department of Materials Science and Engineering Stanford University, Stanford, California 94305, USA
| | - S Uchida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - A Fujimori
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Applied Physics, Waseda University, Shinjuku-ku, Tokyo 169-8555, Japan
| |
Collapse
|
32
|
Kawahara D, Nishibuchi I, Kawamura M, Yoshida T, Nagata Y. Radiomic Analysis for Pretreatment Prediction of Recurrence after Radiotherapy in Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Yoshida T, Nakamura A, Funada J, Amino M, Shimizu W, Fukuzawa M, Watanabe S, Hayashi T, Yamashita T, Okumura K, Akao M. Influence of renal dysfunction on clinical outcomes in elderly patients with atrial fibrillation: a subanalysis of the phase 3, randomized, placebo-controlled ELDERCARE-AF trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Renal dysfunction is common in elderly patients with atrial fibrillation (AF) and is thought to be associated with increased risk of thromboembolic and bleeding events. Once-daily low-dose (15 mg) edoxaban was superior to placebo in preventing stroke or systemic embolic events (S/SEE) without significantly increasing major bleeding events in very elderly (≥80 years) non-valvular AF (NVAF) patients in whom standard oral anticoagulant therapy at approved doses was inappropriate (ELDERCARE-AF trial). Little is known about how renal dysfunction affects the effects of low-dose edoxaban in these patients.
Purpose
We used prespecified subgroup analysis to investigate the relation between renal function (assessed by creatinine clearance, CrCl) and the efficacy and safety of edoxaban in elderly NVAF patients.
Methods
ELDERCARE-AF patients were divided into 3 subgroups according to baseline CrCl: normal renal function/mild dysfunction (CrCl >50 mL/min), moderate renal dysfunction (CrCl ≥30 to ≤50 [“30–50”] mL/min) and severe renal dysfunction (CrCl ≥15 to <30 [“15–30”] mL/min). Primary efficacy and safety endpoints were annualized incidence of S/SEE and ISTH-defined major bleeding, respectively.
Results
Of 984 patients randomized to edoxaban 15 mg or placebo (each group N=492), 681 completed the trial. The 303 discontinuations were due to withdrawal of consent (n=158), death (n=135), or other causes (n=10). Discontinuation rate was the same in the edoxaban and placebo groups. S/SEE incidence in patients with CrCl >50, 30–50 and 15–30 mL/min was 2.0%, 1.3% and 3.5%, respectively, in edoxaban, and 4.4%, 4.6% and 9.7%, respectively, in placebo. In those with CrCl 30–50 and 15–30 mL/min, it was significantly lower in edoxaban than in placebo (adjusted hazard ratio [HR], 0.30 [95% CI, 0.10–0.91], p=0.03; and 0.33 [95% CI, 0.16–0.71], p<0.01, respectively). Incidence of major bleeding in patients with CrCl >50, 30–50 and 15–30 mL/min was 1.0%, 1.8% and 6.2%, respectively, in edoxaban, and 0.9%, 1.5% and 2.4%, respectively, in placebo. Incidence of major bleeding in those with CrCl 15–30 mL/min was higher in edoxaban but not significantly (adjusted HR, 2.53 [95% CI, 0.96–6.72], p=0.062). Incidence of gastrointestinal bleeding in patients with CrCl 15–30 mL/min was 4.3% in edoxaban and 1.6% in placebo (adjusted HR, 2.61 [95% CI, 0.79–8.68], p=0.12). Incidence of all-cause death in patients with CrCl >50, 30–50 and 15–30 mL/min was 5.8%, 6.8% and 15.2%, respectively, in edoxaban, and 7.0%, 6.3% and 15.5%, respectively, in placebo (no significant intergroup differences).
Conclusions
Incidence of S/SEE, major bleeding and all-cause death increased with declining renal function in elderly NVAF patients. Edoxaban 15 mg remained superior to placebo in preventing S/SEE, even in those with moderate to severe renal dysfunction. Incidence of major bleeding in patients with severe renal dysfunction was higher (non-significantly) with edoxaban than with placebo.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi-Sankyo Co., Ltd.
Collapse
Affiliation(s)
- T Yoshida
- Onga Nakama Medical Association Onga Hospital, Onga, Japan
| | - A Nakamura
- Iwate Prefectural Central Hospital, Morioka, Japan
| | - J Funada
- National Hospital Organization Ehime Medical Center, Ehime, Japan
| | - M Amino
- Tokai University, Isehara, Japan
| | - W Shimizu
- Nippon Medical School Hospital, Tokyo, Japan
| | | | | | - T Hayashi
- Daiichi-Sankyo Co., Ltd., Tokyo, Japan
| | | | - K Okumura
- Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - M Akao
- National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | | |
Collapse
|
34
|
Thomas A, Cappuzzo F, Ying C, Yamamoto N, Chen Y, Cortot A, Berghmans T, Reguart Aransay N, Shibata Y, Jianying Z, Yoshida T, Moulin C, Sarholz B, Ferrer-Playan J, Kalapur A, Bolleddula J, Paz-Ares L. 1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
35
|
Nishibata T, Weng J, Omori K, Sato Y, Nakazawa T, Suzuki T, Yamada T, Nakajo I, Kinugasa F, Yoshida T. 986P Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
36
|
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2021; 32:1137-1147. [PMID: 34139272 DOI: 10.1016/j.annonc.2021.06.004] [Citation(s) in RCA: 83] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Revised: 05/26/2021] [Accepted: 06/10/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Between June 2017 and July 2019, this study enrolled treatment-naïve patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations. They were randomly assigned in a 1 : 1 ratio to receive nivolumab or placebo in combination with carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles, followed by nivolumab/placebo with bevacizumab until progressive disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by an independent radiology review committee (IRRC). RESULTS Overall, 550 patients from Japan, Korea, and Taiwan were randomized; of these patients, 273 and 275 received the nivolumab and placebo combinations, respectively. In the present preplanned interim analysis with a median follow up of 13.7 months, the IRRC-assessed median PFS was significantly longer in the nivolumab arm than in the placebo arm (12.1 versus 8.1 months; hazard ratio 0.56; 96.4% confidence interval 0.43-0.71; P < 0.0001). The PFS benefit was observed across all patients with any programmed death-ligand 1 (PD-L1) expression levels including PD-L1-negative patients. The IRRC-assessed objective response rates were 61.5% and 50.5% in the nivolumab and placebo arms, respectively. The incidence of treatment-related adverse events of grade 3 or 4 was comparable between the two arms; treatment-related adverse events leading to death were observed in five and four patients in the nivolumab and placebo arms, respectively. CONCLUSION The TASUKI-52 regimen should be considered a viable new treatment strategy for treatment-naïve patients with advanced nonsquamous NSCLC.
Collapse
Affiliation(s)
- S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan
| | - J-S Lee
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea
| | - J-H Kang
- Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea
| | - H R Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - N Inui
- Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan
| | - T Hida
- Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan
| | - K H Lee
- Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, Korea
| | - T Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - H Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | - C-T Yang
- Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - M Nishio
- Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - T Tamura
- Thoracic Center, St. Luke's International Hospital, Tokyo, Japan
| | - N Yamamoto
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan
| | - C-J Yu
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - H Akamatsu
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan
| | - Y Namba
- Clinical Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan
| | - N Sumiyoshi
- Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
| |
Collapse
|
37
|
Yoshida T, Hashimoto M, Murakami K, Murata K, Nishitani K, Watanabe R, Koyama T, Uehara R, Tanaka M, Ito H, Matsuda S. POS1482-HPR PAIN CATASTROPHIZING IS ASSOCIATED WITH RESIDUAL PAIN AFTER REACHING IMPROVED CONDITIONS OF SWOLLEN/TENDER JOINTS AND SERUM C-REACTIVE PROTEIN LEVEL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:It has long been recognized that immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), are prone to coexist with depression due to the effects of cytokines, and that these two illnesses lead to an elevation in patients’ pain. However, we often encounter patients with RA who suffer from residual pain despite an improvement in disease activity and inflammation. The specific psychological factors associated with residual pain have not yet been clarified. In addition to the traditional psychological factors, such as depression and anxiety, we focused on pain catastrophizing due to the distortion of pain perception and explored its association with residual pain.Objectives:To examine whether psychological factors, such as pain catastrophizing, depression, and anxiety, are associated with self-reported pain visual analogue scale (pain-VAS) scores in RA patients with 1 or less on 28joints- swollen/tender counts (SJC/TJC) and CRP.Methods:This was a cross-sectional study of 290 RA outpatients (85% of whom were women) with scores of less than 1 on SJC, TJC, and CRP, with a median (IQR) age of 66 (57–73) years. The participants completed questionnaires, including pain VAS (0–100 mm), Pain Catastrophizing Scale (PCS, 0–52 scale), and Hospital Depression and Anxiety Scale (HADS, 0–42 scale). Using linear regression analyses, we analysed whether PC (PCS ≥30), depression (HADS-D ≥11), and anxiety (HADS-A ≥11) (independent variables) were associated with pain VAS scores (dependent variable). After univariate regression analysis, multivariate analysis adjusted for confounding factors was performed.Results:Patients reported a wide range of pain severity with a median (range) pain VAS score of 9 (0–96mm). The prevalence of anxiety and depression were 5.5% and 5.9%, respectively. Meanwhile, 24.1% of the patients experienced pain catastrophizing. Pain catastrophizing was associated with pain VAS scores in univariate and multivariate analyses (Table 1). The presence of anxiety and depression was not associated with pain VAS scores in any model. Multivariate analysis of other covariates showed that age, disease duration, and presence of SJC/TJC of joints other than the 28 joints were positively correlated with pain VAS scores.Table 1.Univariate and multivariate regression analysis for independent variables associated with pain-VAS scoresUnivariateMultivariate independent variablesModel 1*Model 2**Pain catastrophizingEstimate3.74.13.695%CI 0.7 to 6.61.1 to 7.00.5 to 6.6p-value0.0150.0060.021AnxietyEstimate3.74.40.595%CI -1.9 to 9.2 -1.0 to 9.9 -3.5 to 7.9p value0.1980.1080.453DepressionEstimate3.54.23.995%CI -1.9 to 8.9 -1.1 to 9.5 -1.9 to 8.7p-value0.2040.1190.210The covariates in multivariate analysis are as follows: age, sex, body mass index, disease duration, Steinbrocker’s Stage, prednisolone dosage, biologic agents use, and presence of swollen joint counts/tender joint counts of joints other than the 28 joints.*Model 1: each psychological independent variable and the above covariates.**Model 2: all psychological independent variables and the above covariates.Conclusion:Pain catastrophizing was associated with pain VAS scores in RA patients with 1 or less on 28joints-SJC/TJC and CRP, emphasising that residual pain in the patients should be treated in a biopsychosocial framework focussing on pain catastrophizing.Disclosure of Interests:Tamami Yoshida: None declared, Motomu Hashimoto Speakers bureau: Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company., Grant/research support from: Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company., Kosaku Murakami Speakers bureau: Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Co; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc., Consultant of: Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Co; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc., Koichi Murata Speakers bureau: Eisai Co., Ltd. and Astellas Pharma Inc., Consultant of: Eisai Co., Ltd. and Astellas Pharma Inc., Kohei Nishitani Grant/research support from: Asahi-Kasei Pharma., Ryu Watanabe Speakers bureau: Mitsubishi Tanabe Pharma Co; Pfizer Inc.; Sanofi S.A.; AbbVie GK; Asahi Kasei Pharma; Eisai Co., Ltd.; Eli Lilly and Company; Bristol-Myers Squibb; and Janssen Pharmaceutical K.K., Teruhide Koyama: None declared, Ritei Uehara: None declared, Masao Tanaka Speakers bureau: AbbVie GK, Asahi Kasei Pharma., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Pfizer Inc., Taisyo Pharma., Ltd., UCB Japan Co., Ltd., Grant/research support from: AbbVie GK, Asahi Kasei Pharma., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Pfizer Inc., Taisyo Pharma., Ltd., UCB Japan Co., Ltd., Hiromu Ito Grant/research support from: Bristol-Myers Squibb, Eisai Co, Taisyo Pharma., and Mochida., Shuichi Matsuda: None declared
Collapse
|
38
|
Yoshida T, Nishimura K, Waki D, Mizukawa K, Tanaka N, Murabe H, Yokota T. POS0824 THE LONG-TERM CLINICAL COURSE OF MUSCULAR VASCULITIS DEPENDING ON THE ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY STATUS: A RETROSPECTIVE OBSERVATIONAL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Skeletal muscle is known as one of the organ involvements of primary systemic vasculitis.1,2 Muscle inflammation is detected by magnetic resonance imaging, and necrotizing vasculitis is proved by muscle biopsy.3 As with systemic vasculitis or single organ vasculitis, glucocorticoid (GC) and immunosuppressants are used in its treatment.4 There are not many reports about muscular vasculitis, and its long-term clinical course after initial treatment, including the rates of relapse and mortality, remains unclear.Objectives:To identify the predictors of relapse and mortality in patients with muscular vasculitis, especially focusing on the status of anti-neutrophil cytoplasmic antibody (ANCA).Methods:We retrospectively reviewed patients diagnosed with necrotizing vasculitis with muscle involvements in our hospital between 2004 and 2020. In all cases, muscular vasculitis was identified by muscle biopsy or magnetic resonance imaging. To focus on the clinical features of muscular vasculitis, we excluded patients with such severe organ involvements as cardiovascular, abdominal, cerebral, severe renal, and severe pulmonary involvements. We compared the 5-year cumulative incidence of relapse, the overall survival rate, and the dose of GC over 5 years between the ANCA-positive and ANCA-negative groups. A relapse was defined as any new or worsened state of disease activity requiring an escalation of GC dose. Gray’s method was used for assessing the cumulative incidence of relapse. The log-rank test was used for assessing overall survival. The Mann-Whitney U test was used for assessing the dose of GC. The possible factors for relapse in 5 years in a univariate analysis were selected for a multivariate analysis using the Cox proportional hazards model.Results:Forty-nine patients were enrolled. The median age of onset was 77 (69-82) years and 71.4% were women. There were 30 ANCA-positive patients (90.0% with anti-myeloperoxidase) and 19 ANCA-negative patients. The median age and the number of patients with renal involvements were higher in the ANCA-positive group than in the ANCA-negative group (73.0 ± 9.29 years vs. 79.5 ± 20.28 years, p=0.0062 and 7/30 [23.3%] vs. 0/19 [0.0%], p=0.034, respectively). The Birmingham Vasculitis Activity Score (ver. 3), the induction dose of GC, and the rate of immunosuppressants use were not significantly different between the two groups. During the observational period, 24 patients relapsed. The 5-year cumulative incidence of relapse was significantly higher in the ANCA-positive group than in the ANCA-negative group (p=0.026) (Figure 1). The Cox proportional hazards model revealed that the presence of ANCA was an independent risk factor for relapse (hazard ratio: 3.15; 95% confidence interval 1.06–9.38; p=0.040). During the observational period, 9 patients died (3 died from cancer, 1 from interstitial pneumonia, 1 from cerebral hemorrhage, 1 from infection, and 3 from unknown reasons). The ANCA-positive group exhibited a higher mortality rate than the ANCA-negative group without a statistical significance (p=0.12). The 5-year cumulative dose of GC was larger in the ANCA-positive group than in the ANCA-negative group without a statistical significance (14786 [11246–19138] mg vs. 10088 [7129–12634] mg, p=0.12).Conclusion:In muscular vasculitis, the presence of ANCA is an independent risk factor for long-term relapse. Stratified treatment depending on the ANCA status may reduce the relapse rate and the occurrence of side effects of GC in patients with muscular vasculitis.References:[1]Kitching AR et al. Nat Rev Dis Primers 2020; 6(1): 71.[2]Hernández-Rodríguez J et al. J Autoimmun 2014; 48-49: 84-9.[3]Ushiyama S et al. Rheumatol Int 2020; 40(10): 1667-74.[4]Ganeshanandan LR et al. Semin Arthritis Rheum 2020; 50(3): 503-8.Disclosure of Interests:None declared
Collapse
|
39
|
Tsuda S, Tanigaki M, Yoshida T, Okumura R, Saito K. ANALYSES OF H*(10) DOSE RATES MEASURED IN ENVIRONMENT CONTAMINATED BY RADIOACTIVE CAESIUM: CORRECTION OF DIRECTIONAL DEPENDENCE OF SCINTILLATION DETECTORS. Radiat Prot Dosimetry 2021; 193:228-236. [PMID: 33893735 DOI: 10.1093/rpd/ncab060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 03/08/2021] [Accepted: 04/01/2021] [Indexed: 06/12/2023]
Abstract
Ambient dose equivalent rates were measured in the environment of the Fukushima prefecture using NaI(Tl)/CsI(Tl) scintillation detectors and CdZnTe/Ge semiconductor detectors. The dose rates obtained at the same locations varied beyond uncertainty (1σ). By replacing the spectrum-dose conversion operators obtained from the anterior-posterior geometry with those from the rotational geometry, the dose rates agreed with each other within uncertainties, except for a CsI(Tl) scintillation detector with a considerably flat crystal configuration, due to its excessive directional dependence.
Collapse
Affiliation(s)
- S Tsuda
- Research group for radiation transport analysis, Japan Atomic Energy Agency, 2-4, Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - M Tanigaki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - T Yoshida
- Emergency Administration Section, Japan Atomic Energy Agency, 765-1 Funaishikawa, Tokai-mura, Naka-gun, Ibaraki 319-1184, Japan
| | - R Okumura
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - K Saito
- Sector of Nuclear Safety Research and Emergency Preparedness, Japan Atomic Energy Agency, 148-4 Kashiwanoha Campus,178-4 Wakashiba, Kashiwa-city, Chiba, 277-0871, Japan
| |
Collapse
|
40
|
Takeuchi A, Uemura A, Goya S, Shimada K, Yoshida T, Hara S, Sato K, Shiraishi K, Yairo A, Kto K, Matsuura K, Tanaka R. The utility of patent ductus arteriosus closure with hemostatic clip in dogs. Pol J Vet Sci 2021; 23:255-260. [PMID: 32627978 DOI: 10.24425/pjvs.2020.133640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
This study investigated the utility of patent ductus arteriosus (PDA) closure with hemostatic clip by comparing with traditional PDA closure. Medical records of 51 dogs with surgical closure of PDA were reviewed and retrospective study was conducted. 29 dogs were treated by procedure with hemostatic clip (Group HC), and 22 dogs were treated by surgical ligation (Group SL). Data pertaining to breed, sex, age and body weight at the time of surgery, echocardiographic minimal ductal diameter, duration of surgery, hemostatic clip size, echocardiographic findings, hemor-rhage, residual ductal flow and recanalization were collected from records. The results showed that procedure with hemostatic clip had been selected in lighter dogs than traditional PDA closure. Duration of surgery performed only hemostatic clip technique was significantly shorter than that in group SL. Preoperative LVIDd, E-wave and FS were significantly lower than postoperative ones. As regard all parameters, the differences between pre- and postoperative periods were not significantly different between group HC and group SL. Hemorrhage, residual ductal flow, and recanalization were not significantly different in both groups. The present study showed that procedure with hemostatic clip is beneficial in that it is available in smaller dogs and can make shorter operation duration than traditional PDA closure. Moreover, the procedure is effective for the resolution of volume overload of the left atrium and ventricle in short-term outcome. Complications including hemorrhage, residual ductal flow and recanaliza-tion were not significantly different with both techniques.
Collapse
Affiliation(s)
- A Takeuchi
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - A Uemura
- Graduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8572, Japan
| | - S Goya
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - K Shimada
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - T Yoshida
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - S Hara
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - K Sato
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - K Shiraishi
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - A Yairo
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - K Kto
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - K Matsuura
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| | - R Tanaka
- Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai, Fuchu, Tokyo, 183-8509, Japan
| |
Collapse
|
41
|
Mathevosian S, Yoshida T, Hassani C, Jalili M, Finn P, Bedayat A. Abstract No. 468 Evaluation of aortic stent endoleaks using ferumoxytol-enhanced magnetic resonance angiography. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
42
|
Forman J, Yoshida T, Lillis J, Gill A, Corbett A, Cahill M, Lockhart A, Simpson E, Boguniewicz M, Hanifin J, De Benedetto A, David G, Leung D, Schlievert P, Gill S, Beck L. 189 Microbial expression of lantibiotics may explain discrepancies between S. aureus culturability and metagenomics in atopic dermatitis subjects and healthy controls. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Beck L, Boguniewicz M, Hatta T, Chiesa Fuxench Z, Simpson E, De Benedetto A, Ko J, Ong P, Yoshida T, Gallo R, Schlievert P, Gill S, Mosmann T, Berdyshev E, David G, Lussier S, Rudman Spergel A, Leung D. 666 Effect of dupilumab on the host-microbe interface in atopic dermatitis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Pandya R, Beck L, Yoshida T. 227 Effect of triamcinolone & manuka honey on Staphylococcus aureus growth & hemolytic activity. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Isagawa S, Shiohira H, Hokama N, Nitta H, Yoshida T, Masamoto H, Aoki Y, Nakamura K. Measurement of zinc concentration in blood and breast milk of a Wilson's disease patient taking zinc acetate. Pharmazie 2021; 75:177-178. [PMID: 32393423 DOI: 10.1691/ph.2020.9765] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Case: A 27-year-old, gravida 2, para 0, Japanese female who was maintained on zinc acetate (75 mg/day) during pregnancy expressed her desire to breastfeed after birth. We investigated the possibility of breastfeeding while on treatment. Breast milk zinc concentrations were determined using an atomic absorption photometer. Breast milk zinc concentrations on the 4th (colostrum) and 32nd (post-colostrum) days post partum were 10.80 μg/mL and 3.28 μg/mL, respectively. These values are less than the reported range of breast milk zinc concentrations in Japanese women who are not under any medication. Conclusion: We measured blood and breast milk zinc concentrations of a patient with Wilson's disease who was taking zinc acetate (75 mg/day). Zinc values were within the range of breast milk concentrations of mothers who are not on zinc acetate.
Collapse
Affiliation(s)
- S Isagawa
- Department of Pharmacy, University of the Ryukyus Hospital, Okinawa, Japan
| | - H Shiohira
- Department of Pharmacy, University of the Ryukyus Hospital, Okinawa, Japan
| | - N Hokama
- Department of Pharmacy, University of the Ryukyus Hospital, Okinawa, Japan
| | - H Nitta
- Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
| | - T Yoshida
- Department of Pediatrics, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
| | - H Masamoto
- Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
| | - Y Aoki
- Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
| | - K Nakamura
- Department of Pharmacy, University of the Ryukyus Hospital, Okinawa, Japan;,
| |
Collapse
|
46
|
Motoi N, Yoshida H, Kiyuna T, Saiga H, Horinouchi H, Yoshida T, Watanabe S, Ohe Y, Ochiai A. FP07.04 Predictive Efficacy of Morphological Biomarkers Based on Digital Pathology for ICI Therapy of Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Abe K, Bronner C, Hayato Y, Ikeda M, Imaizumi S, Ito H, Kameda J, Kataoka Y, Miura M, Moriyama S, Nagao Y, Nakahata M, Nakajima Y, Nakayama S, Okada T, Okamoto K, Orii A, Pronost G, Sekiya H, Shiozawa M, Sonoda Y, Suzuki Y, Takeda A, Takemoto Y, Takenaka A, Tanaka H, Yano T, Akutsu R, Han S, Kajita T, Okumura K, Tashiro T, Wang R, Xia J, Bravo-Berguño D, Labarga L, Marti L, Zaldivar B, Blaszczyk F, Kearns E, Gustafson J, Raaf J, Stone J, Wan L, Wester T, Bian J, Griskevich N, Kropp W, Locke S, Mine S, Smy M, Sobel H, Takhistov V, Weatherly P, Hill J, Kim J, Lim I, Park R, Bodur B, Scholberg K, Walter C, Coffani A, Drapier O, El Hedri S, Giampaolo A, Gonin M, Mueller T, Paganini P, Quilain B, Ishizuka T, Nakamura T, Jang J, Learned J, Anthony L, Sztuc A, Uchida Y, Berardi V, Catanesi M, Radicioni E, Calabria N, Machado L, De Rosa G, Collazuol G, Iacob F, Lamoureux M, Ospina N, Ludovici L, Nishimura Y, Cao S, Friend M, Hasegawa T, Ishida T, Kobayashi T, Matsubara T, Nakadaira T, Jakkapu M, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Nakano Y, Shiozawa T, Suzuki A, Takeuchi Y, Yamamoto S, Ali A, Ashida Y, Feng J, Hirota S, Ichikawa A, Kikawa T, Mori M, Nakaya T, Wendell R, Yasutome K, Fernandez P, McCauley N, Mehta P, Pritchard A, Tsui K, Fukuda Y, Itow Y, Menjo H, Niwa T, Sato K, Tsukada M, Mijakowski P, Posiadala-Zezula M, Jung C, Vilela C, Wilking M, Yanagisawa C, Harada M, Hagiwara K, Horai T, Ishino H, Ito S, Koshio Y, Ma W, Piplani N, Sakai S, Kuno Y, Barr G, Barrow D, Cook L, Goldsack A, Samani S, Simpson C, Wark D, Nova F, Boschi T, Di Lodovico F, Molina Sedgwick S, Taani M, Zsoldos S, Yang J, Jenkins S, McElwee J, Thiesse M, Thompson L, Malek M, Stone O, Okazawa H, Kim S, Yu I, Nishijima K, Koshiba M, Ogawa N, Iwamoto K, Yokoyama M, Martens K, Vagins M, Kuze M, Izumiyama S, Tanaka M, Yoshida T, Inomoto M, Ishitsuka M, Matsumoto R, Ohta K, Shinoki M, Martin J, Tanaka H, Towstego T, Hartz M, Konaka A, de Perio P, Prouse N, Pointon B, Chen S, Xu B, Richards B, Jamieson B, Walker J, Minamino A, Okamoto K, Pintaudi G, Sasaki R. Neutron-antineutron oscillation search using a 0.37 megaton-years exposure of Super-Kamiokande. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.103.012008] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
48
|
Yamada Y, Yoshida T, Nakagata T, Nanri H, Miyachi M. Letter to the Editor: Age, Sex, and Regional Differences in the Effect of COVID-19 Pandemic on Objective Physical Activity in Japan: A 2-Year Nationwide Longitudinal Study. J Nutr Health Aging 2021; 25:1032-1033. [PMID: 34545926 PMCID: PMC8322639 DOI: 10.1007/s12603-021-1662-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 06/23/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Y Yamada
- Yosuke Yamada, PhD, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan,
| | | | | | | | | |
Collapse
|
49
|
Singh AK, Praharaj M, Lombardo KA, Yoshida T, Matoso A, Baras AS, Zhao L, Prasad P, Srikrishna G, Powell JD, Kates M, McConkey D, Pardoll DM, Bishai WR, Bivalacqua TJ. Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer. Urol Oncol 2020. [DOI: 10.1016/j.urolonc.2020.10.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Yoshida T, Shibata A, Tanihata A, Hayashi H, Ichikawa Y, Ishikawa H, Yamaguchi Y, Kitada R, Ehara S, Izumiya Y, Yoshiyama M. Thigh intramuscular fat predicts the prognosis in patients in non-ischemic cardiomyopathy with reduced ejection fraction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Skeletal muscle atrophy is an independent prognostic predictor for patients with chronic heart failure, and the concept of sarcopenia is drawing attention. Furthermore, the importance of not only muscle mass but also intramuscular fat (IMF) has been pointed out. However, there is a lack of consensus on the implications of ectopic fat for the prognosis in patients with non-ischemic cardiomyopathy.
Purpose
We investigated whether ectopic fat in the thigh affects the prognosis with non-ischemic cardiomyopathy.
Methods
We recruited 105 patients who were diagnosed with non-ischemic cardiomyopathy by cardiac catheterization and echocardiographic date between September 2017 and November 2019. Finally 73 patients with reduced EF (EF 40% or less) enrolled in this prospective study. Functional status was evaluated by using cardiopulmonary exercise test at baseline. All patients were measured quantity of epicardial fat and thigh IMF percentage (%IMF) using computed tomography scan. Demographic, laboratory and echocardiographic date were collected from the patients' medical records. Clinical endpoints were unexpected readmission.
Results
During the follow-up period 18 patients had adverse events. The %IMF was significantly higher in the group with adverse events than without (5.57±5.70 and 3.02±2.44%, respectively; p<0.01). Spearman correlation coefficient analysis showed a modest correlation between %IMF and lower limb extension strength (Spearman r=−0.280; p=0.0315), but there was no significant correlation between %IMF and exercise tolerance such as anaerobic threshold and peak oxygen uptake. Patients were divided into 2 groups according to the median values of %IMF. Kaplan-Meier analysis demonstrated that events were significantly higher in the high %IMF group (log-rank p=0.033). Multivariate Cox regression analysis adjusted for left ventricular end-diastolic diameter and peak ventricular oxygen consumption found %IMF as an independent factor of adverse events (hazard ratio 1.545; 95% confidential interval 1.151–2.087; p=0.004).
Conclusions
In non-ischemic cardiomyopathy patients with reduced EF, %IMF may have important adverse consequences such as increased cardiac-related events.
Kaplan-Meier curves
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - A Shibata
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - A Tanihata
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Hayashi
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Ichikawa
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Ishikawa
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Yamaguchi
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - R Kitada
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Ehara
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Izumiya
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Yoshiyama
- Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|